bioAffinity Technologies, Inc. (NASDAQ:BIAF) Stock Short Interest Report for October

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 66,654 shares, a decline of 42.3% from the September 30th total of 115,467 shares. Based on an average daily trading volume, of 3,440,106 shares, the days-to-cover ratio is currently 0.0 days. Currently, 11.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

BIAF has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, bioAffinity Technologies has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in bioAffinity Technologies stock. J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 42,600 shares of the company’s stock, valued at approximately $164,000. J. Safra Sarasin Holding AG owned 0.95% of bioAffinity Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Price Performance

Shares of NASDAQ:BIAF traded down $0.12 during trading hours on Friday, hitting $2.91. 46,402 shares of the company’s stock traded hands, compared to its average volume of 1,964,175. The company’s fifty day simple moving average is $6.15 and its two-hundred day simple moving average is $19.11. The company has a market cap of $1.75 million, a price-to-earnings ratio of -0.03 and a beta of -1.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.41 and a current ratio of 1.44. bioAffinity Technologies has a 52 week low of $2.66 and a 52 week high of $80.70.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($31.50) by $30.86. The firm had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 220.52%.

About bioAffinity Technologies

bioAffinity Technologies, Inc is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment.

Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods.